Entrada Therapeutics, Inc.(TRDA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TRDA Entrada Therapeutics, Inc.

盘前交易 03-03 05:44:51 EST

11.68

-0.25

-2.10%

最高12.00	最低11.21	成交量28.48万
今开11.79	昨收11.93	日振幅6.62%
总市值4.46亿	流通市值2.52亿	总股本3,822万
成交额332.80万	换手率1.32%	流通股本2,158万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TRDA","market":"US","secType":"STK","nameCN":"Entrada Therapeutics, Inc.","latestPrice":11.68,"timestamp":1772485200000,"preClose":11.93,"halted":0,"volume":284818,"delay":0,"changeRate":-0.020955574182732608,"floatShares":21582000,"shares":38219232,"eps":-3.474615,"marketStatus":"盘前交易","change":-0.25,"latestTime":"03-03 05:44:51 EST","open":11.79,"high":12,"low":11.21,"amount":3328002.346334,"amplitude":0.06622,"askPrice":17.91,"askSize":100,"bidPrice":8.69,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.474615,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772548200000},"marketStatusCode":1,"adr":0,"listingDate":1635480000000,"exchange":"NASDAQ","adjPreClose":11.68,"postHourTrading":{"tag":"盘后","latestPrice":11.68,"preClose":11.68,"latestTime":"17:03 EST","volume":2050,"amount":23949.16,"timestamp":1772488985516,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.4023935690235174,"impliedVol":0.2315,"impliedVolPercentile":0.068},"requestUrl":"/m/hq/s/TRDA","defaultTab":"news","newsList":[{"id":"1140741050","title":"Entrada Therapeutics计划2026年底前启动ENTR-601-50全球1/2期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1140741050","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140741050?lang=zh_cn&edition=full","pubTime":"2026-01-08 20:12","pubTimestamp":1767874341,"startTime":"0","endTime":"0","summary":"生物技术公司Entrada Therapeutics宣布，预计将在2026年年底前启动其候选药物ENTR-601-50的全球性1/2期多次给药（MAD）临床研究。这一时间表标志着该公司在推进其研发管线方面迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TRDA"],"gpt_icon":0},{"id":"1161618850","title":"Entrada Therapeutics公司预计2026年第二季度公布Elevate-44-201首组数据，年中披露Elevate-45-201首组数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1161618850","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161618850?lang=zh_cn&edition=full","pubTime":"2026-01-08 20:10","pubTimestamp":1767874239,"startTime":"0","endTime":"0","summary":"生物技术公司Entrada Therapeutics Inc（TRDA）宣布其临床研究计划正稳步推进。根据最新时间表，公司将在2026年第二季度公布Elevate-44-201试验首组患者的研究数据，并于2026年年中发布Elevate-45-201试验的首组数据。这两项关键临床数据的披露将为企业后续研发决策提供重要依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TRDA"],"gpt_icon":0},{"id":"1154777080","title":"Entrada Therapeutics预计现金使用期延长至2027年第三季度，截止至9月30日现金、现金等价物及可交易证券合计达3.27亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1154777080","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154777080?lang=zh_cn&edition=full","pubTime":"2025-11-06 20:25","pubTimestamp":1762431917,"startTime":"0","endTime":"0","summary":"Entrada Therapeutics预计现金使用期延长至2027年第三季度，截止至9月30日现金、现金等价物及可交易证券合计达3.27亿美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRDA","BK4139"],"gpt_icon":0},{"id":"1142220963","title":"Entrada Therapeutics 2024年第四季度GAAP每股收益$0.03超过预期$(0.67)，销售额$37.40M超过预期$13.12M","url":"https://stock-news.laohu8.com/highlight/detail?id=1142220963","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142220963?lang=zh_cn&edition=full","pubTime":"2025-02-27 20:12","pubTimestamp":1740658350,"startTime":"0","endTime":"0","summary":"Entrada Therapeutics  公布季度每股收益为$0.03，超过分析师一致预期$，超出104.48%。公司季度销售额为$37.40百万，超过分析师一致预期的$13.12百万，超出185.04%。与去年同期$41.85百万的销售额相比，减少了10.63%。以上内容来自Benzinga Earnings专栏，原文如下：Entrada $Therapeutics$  reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $ by 104.48 percent. This is a 110.34 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $37.40 million which beat the analyst consensus estimate of $13.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","TRDA"],"gpt_icon":0},{"id":"2478372279","title":"Entrada Therapeutics, Inc.盘中异动 早盘股价大涨5.23%报17.72美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2478372279","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478372279?lang=zh_cn&edition=full","pubTime":"2024-10-25 23:07","pubTimestamp":1729868847,"startTime":"0","endTime":"0","summary":"北京时间2024年10月25日23时07分，Entrada Therapeutics, Inc.股票出现波动，股价大幅拉升5.23%。Entrada Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.85%。Entrada Therapeutics, Inc.公司简介：Entrada Therapeutics Inc临床阶段生物制药公司，旨在通过建立一类新的药物来改变患者的生活，这些药物涉及长期以来被认为难以接近的细胞内靶点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102523072798e3e89c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102523072798e3e89c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TRDA","LENZ","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.entradatx.com","stockEarnings":[{"period":"1week","weight":0.0345},{"period":"1month","weight":0.021},{"period":"3month","weight":0.1858},{"period":"6month","weight":1.1955},{"period":"1year","weight":-0.0218},{"period":"ytd","weight":0.1362}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0081},{"period":"3month","weight":0.0071},{"period":"6month","weight":0.0662},{"period":"1year","weight":0.1552},{"period":"ytd","weight":0.0065}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Entrada Therapeutics, Inc.于2016年9月22日根据特拉华州法律注册成立。该公司旨在通过将内体逃逸载体(EEV)疗法确立为一种新型药物来改变患者的生活，并致力于成为世界上最重要的细胞内疗法公司。该公司的EEV疗法旨在处理长期以来被认为无法接近和无法成药的细胞内靶标。通过其专有的、高度通用的模块化EEV平台，该公司正在构建强大的EEV治疗候选药物开发组合，旨在使治疗剂在各种器官和组织中有效细胞内递送，并提高治疗指数。该公司相信，早期项目的潜在成功可以转化为有效开发其他EEV治疗候选药物，并能够在罕见疾病、免疫学和肿瘤学方面建立投资组合。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.119802},{"month":2,"riseRate":0.6,"avgChangeRate":-0.003122},{"month":3,"riseRate":0.4,"avgChangeRate":-0.056283},{"month":4,"riseRate":0.25,"avgChangeRate":-0.177334},{"month":5,"riseRate":0.5,"avgChangeRate":0.061748},{"month":6,"riseRate":0.5,"avgChangeRate":0.23206},{"month":7,"riseRate":0.75,"avgChangeRate":0.057246},{"month":8,"riseRate":0.25,"avgChangeRate":-0.040222},{"month":9,"riseRate":0.75,"avgChangeRate":0.071087},{"month":10,"riseRate":1,"avgChangeRate":0.182556},{"month":11,"riseRate":0.6,"avgChangeRate":0.06971},{"month":12,"riseRate":0.4,"avgChangeRate":-0.097654}],"exchange":"NASDAQ","name":"Entrada Therapeutics, Inc.","nameEN":"Entrada Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Entrada Therapeutics, Inc.(TRDA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Entrada Therapeutics, Inc.(TRDA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Entrada Therapeutics, Inc.,TRDA,Entrada Therapeutics, Inc.股票,Entrada Therapeutics, Inc.股票老虎,Entrada Therapeutics, Inc.股票老虎国际,Entrada Therapeutics, Inc.行情,Entrada Therapeutics, Inc.股票行情,Entrada Therapeutics, Inc.股价,Entrada Therapeutics, Inc.股市,Entrada Therapeutics, Inc.股票价格,Entrada Therapeutics, Inc.股票交易,Entrada Therapeutics, Inc.股票购买,Entrada Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Entrada Therapeutics, Inc.(TRDA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Entrada Therapeutics, Inc.(TRDA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}